Advanced Epithelial Ovarian Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Ovarian malignancies include primary lesions brought on by healthy ovarian structures and secondary lesions brought on by cancer growing elsewhere in the body. There are several uncommon primary lesions, such as germ cell tumors, germ cell stromal tumors, and epithelial ovarian cancer (which makes up 70% of all ovarian malignancies). With over 313,000 new cases and over 207,000 fatalities in 2020, ovarian cancer will rank as the eighth most common cancer in women globally and the 18th most common cancer overall. There are 6.6 cases per 100,000 people worldwide, with Brunei having the highest rate (17.4). Based on data from 2015 to 2019, the incidence of ovarian cancer in the United States is 10.6 per 100,000 women annually. cases throughout the year. If the patient is in good health, surgery is frequently the preferred course of treatment for ovarian cancer. Patients who are not a good candidate for optimal weight loss should be thought about for neoadjuvant chemotherapy, which would be followed by intermittent surgery and additional chemotherapy. Chemotherapy may be given to patients who are not candidates for surgery before either chemotherapy or surgery is considered.

Description

Primary lesions brought on by healthy ovarian structures make up ovarian malignancies, while secondary lesions brought on by cancer spreading from one place in the body to another make up secondary lesions. Germ cell tumors, germ cell stromal tumors, and other uncommon types are examples of primary lesions. Epithelial ovarian cancer makes up 70% of all ovarian malignancies. The most frequent cause of death from gynecological cancer is epithelial ovarian cancer, which typically manifests itself at a late stage. In order to increase the precision and effectiveness of treatment, epithelial ovarian cancer enables the identification of predictors of response, such as mutations in the breast cancer susceptibility genes BRCA1 and BRCA2, and inhibitors of the DNA damage response or resistance pathways (cyclin E1).

Advanced Epithelial Ovarian Cancer (Epidemiology)

With more than 313,000 new cases and more than 207,000 fatalities in 2020, ovarian cancer will rank as the eighth most common cancer in women worldwide. 6.6 cases are reported for every 100,000 people worldwide, with Brunei having the highest rate at 17.4. Ovarian cancer affects 10.6 per 100,000 women annually in the United States, according to data from 2015 to 2019. Ovarian cancer incidence has decreased by about 1% in women under the age of 65 since at least the mid-1970s, and by about 1% in older women since the early 1990s. Whites had an ovarian cancer incidence rate of 11.0 cases per 100,000 women per year compared to Blacks' 9.1 cases. Girls as young as 15 years old can develop epithelial ovarian cancer, but the average age at diagnosis is 63, and the majority of cases are discovered in women between the ages of 55 and 64. A lifetime risk of 1.22% is thought to exist in the United States. The American Cancer Society predicts that 12,810 women will die from the disease in 2022, with 19.88 new cases of ovarian cancer being diagnosed. Despite being the 18th most prevalent cancer in women, ovarian cancer is the fifth most common cause of cancer-related death in females, accounting for 5% of all cancer-related deaths-more than any other cancer of the female reproductive system.

Advanced Epithelial Ovarian Cancer -Current Market Size & Forecast Trends

The market for advanced epithelial ovarian cancer is anticipated to grow significantly, with estimates indicating a value of approximately USD 3.5 billion in 2023 and projected to reach around USD 6.1 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.3% during this period. The growth is driven by the rising incidence of ovarian cancer, increased awareness of symptoms, advancements in diagnostic technologies, and the development of new treatment options such as targeted therapies and immunotherapies. Additionally, ongoing research into personalized medicine and the increasing number of clinical trials exploring novel agents are expected to further enhance market dynamics. North America is likely to dominate the market due to its advanced healthcare infrastructure and significant investments in cancer research. Overall, the advanced epithelial ovarian cancer market is well-positioned for substantial growth through 2035 as new therapies and treatment strategies continue to emerge.

Epithelial ovarian cancer in women is still being treated with a variety of medical and surgical techniques. A lot has been accomplished over the last few years, and ground-breaking clinical trials have supported it. Neoadjuvant chemotherapy followed by interval debulking surgery is an alternative for a particular subset of patients, such as those who are older, women with a significant disease burden, or those with multiple comorbidities. Primary debulking surgery is generally preferred. Even though systemic therapy and surgery are still used to treat primary epithelial ovarian cancer, more intricate surgical techniques and cutting-edge therapeutics are now considered the gold standard of care. Cytotoxic chemotherapy and aggressive surgical intervention continue to be standard treatments, but targeted therapies are gaining popularity and new information has questioned the value of surgery for women with recurrent disease. The publication of GOG 172 in 2006 led to the standardization of intraperitoneal chemotherapy in North America. In comparison to women who received intravenous chemotherapy, the researchers discovered a 16-month overall survival benefit for those who received intraperitoneal chemotherapy. Poly ADP-ribose polymerase inhibitors have improved outcomes for progression-free survival in both the frontline and recurrent settings, and their use is becoming more common. New biomarker-driven drug approvals suggest that women may benefit from somatic molecular testing as well, and the recent development of treatment categories based on genetic changes supports the recommendation that all women with epithelial ovarian cancer undergo germline genetic testing.

Report Highlights

Advanced Epithelial Ovarian Cancer - Current Market Trends

Advanced Epithelial Ovarian Cancer - Current & Forecasted Cases across the G8 Countries

Advanced Epithelial Ovarian Cancer - Market Opportunities and Sales Potential for Agents

Advanced Epithelial Ovarian Cancer - Patient-based Market Forecast to 2035

Advanced Epithelial Ovarian Cancer - Untapped Business Opportunities

Advanced Epithelial Ovarian Cancer - Product Positioning Vis-a-vis Competitors' Products

Advanced Epithelial Ovarian Cancer - KOLs Insight